FDA warns against the usage of Remdesivir along with malaria antiviral Hydroxychloroquine

▴ FDA warns against the usage of Remdesivir along with malaria antiviral Hydroxychloroquine
Remdesivir and HCQ is a deadly combination, reports US FDA

The FDA  warned yesterday, about possible interactions between the drugs and remdesivir, an antiviral drug that has shown effectiveness against COVID-19. Remdesivir, made by Gilead and delivered intravenously, has received emergency use authorization for the treatment of hospitalized COVID-19 patients with severe disease.

The FDA said that based on a lab study, it is revising its fact sheet for health care providers to say the combination of therapies could reduce remdesivir's antiviral activity.Hydroxychloroquine and chloroquine drugs are still available for alternate uses, so U.S. doctors could prescribe them for COVID-19 – a practice known as off-label prescribing.

Hydroxychloroquine is an arthritis medicine that can be used to prevent or treat malaria, a red blood cell infection transmitted by a mosquito bite, according to the Mayo Clinic. It’s available in the USA by prescription only and can be administered either as a pill or by intravenous drip.

The long list of common side effects of the malaria drug, under the brand name Plaquenil, include nausea, vomiting, stomach pain or cramps, loss of appetite, weight loss, diarrhea, dizziness, spinning sensation, headache, ringing in the ears, nervousness, irritability, skin rash, itching or hair loss.

The drug came to public attention after several small, anecdotal, non-peer-reviewed reports about hydroxychloroquine in China in February. None was up to the scientific gold standard of a double-blind, randomized, placebo-controlled trial that would more definitively show whether the drug worked.

President Trump spoke about hydroxychloroquine given together with the antibiotic azithromycin on March 19. He touted them numerous times in various media and at public events.

Since late April, Trump had toned down his support of the drug, but during a roundtable discussion with restaurant executives at the White House May 18, he said he was taking the drug.

The World Health Organization announced around the same time a "temporary pause" on the drug's inclusion in a global study on potential treatments for the disease in light of a study published in The Lancet that found a lower survival rate among hospitalized COVID-19 patients using the drug. The study was later retracted.

Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except for informal studies. Meanwhile, the U.S. Food and Drug Administration also revoked its emergency authorization for hydroxychloroquine, a controversial malaria drug promoted by President Donald Trump for treating the coronavirus.

The agency said in a letter the decision is based on new evidence that made it unreasonable to believe hydroxychloroquine and chloroquine "may be effective in diagnosing, treating or preventing" COVID-19, the illness caused by the virus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.

Shipments of the drugs obtained by the federal government from the National Stockpile will no longer be distributed to state and local health authorities. On April 13, Trump announced his administration deployed roughly 29 million doses of hydroxychloroquine.

Tags : #US #USFDA #Remdesivir #Malaria #Arthritis #HCQ #GileadSciences #CoronavirusUpdate #USCovidUpdate

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026